Key Points
- Sukumar Nagendran sold 260,047 shares of Taysha Gene Therapies on Dec. 1 at an average price of $4.51 for about $1.17M, trimming his stake by 20.53% to 1,006,439 shares valued at roughly $4.54M.
- Taysha (TSHA) opened at $4.43 and was trading down ~6.5%, has a 52‑week range of $1.05–$5.51 and a market cap around $1.21B, while analysts maintain a Moderate Buy consensus with a $10.30 target and institutions hold about 77.7% of the stock.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) insider Sukumar Nagendran sold 110,125 shares of Taysha Gene Therapies stock in a transaction on Friday, November 28th. The stock was sold at an average price of $4.75, for a total transaction of $523,093.75. Following the sale, the insider directly owned 1,006,439 shares of the company's stock, valued at $4,780,585.25. This represents a 9.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Sukumar Nagendran also recently made the following trade(s):
- On Monday, December 1st, Sukumar Nagendran sold 260,047 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.51, for a total value of $1,172,811.97.
- On Wednesday, September 10th, Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $3.23, for a total value of $646,000.00.
Taysha Gene Therapies Stock Down 6.5%
Shares of Taysha Gene Therapies stock opened at $4.43 on Tuesday. The business has a fifty day simple moving average of $4.40 and a 200 day simple moving average of $3.32. The stock has a market cap of $1.21 billion, a PE ratio of -13.42 and a beta of 1.06. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies, Inc. has a 12 month low of $1.05 and a 12 month high of $5.51.
Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. Research analysts predict that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.
Wall Street Analysts Forecast Growth
TSHA has been the topic of several recent analyst reports. Raymond James Financial initiated coverage on shares of Taysha Gene Therapies in a research note on Tuesday, October 21st. They set a "strong-buy" rating and a $13.00 price objective on the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $13.00 price target on shares of Taysha Gene Therapies in a research report on Friday, November 14th. Robert W. Baird boosted their price target on shares of Taysha Gene Therapies from $7.00 to $12.00 and gave the company an "outperform" rating in a report on Thursday, October 2nd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Taysha Gene Therapies in a research note on Tuesday, November 25th. Finally, Citizens Jmp lifted their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a "market outperform" rating in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $10.30.
View Our Latest Analysis on TSHA
Institutional Investors Weigh In On Taysha Gene Therapies
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. ST Germain D J Co. Inc. lifted its position in Taysha Gene Therapies by 81.8% in the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company's stock valued at $32,000 after acquiring an additional 4,333 shares in the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new stake in shares of Taysha Gene Therapies in the 3rd quarter valued at about $40,000. Marex Group plc acquired a new stake in shares of Taysha Gene Therapies in the 2nd quarter valued at about $29,000. E Fund Management Co. Ltd. bought a new stake in shares of Taysha Gene Therapies in the second quarter valued at about $31,000. Finally, Allegheny Financial Group acquired a new position in shares of Taysha Gene Therapies during the third quarter worth about $49,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.
Taysha Gene Therapies Company Profile
(
Get Free Report)
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
